HC Wainwright Reaffirms “Buy” Rating for Rani Therapeutics (NASDAQ:RANI)

Rani Therapeutics (NASDAQ:RANI)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $9.00 price target on the stock.

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a $9.00 price objective on shares of Rani Therapeutics in a report on Wednesday, February 26th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $12.33.

Rani Therapeutics Trading Down 6.9 %

Shares of Rani Therapeutics stock opened at $1.21 on Thursday. The company has a 50 day simple moving average of $1.50 and a two-hundred day simple moving average of $1.80. The firm has a market cap of $69.32 million, a PE ratio of -1.14 and a beta of 0.14. Rani Therapeutics has a 1 year low of $1.17 and a 1 year high of $8.75. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). The firm had revenue of $1.03 million for the quarter. Analysts expect that Rani Therapeutics will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Rani Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC bought a new stake in shares of Rani Therapeutics in the 4th quarter valued at about $37,000. Virtu Financial LLC bought a new stake in Rani Therapeutics in the fourth quarter valued at approximately $62,000. Insigneo Advisory Services LLC purchased a new stake in shares of Rani Therapeutics during the fourth quarter valued at approximately $65,000. Two Sigma Advisers LP bought a new position in shares of Rani Therapeutics in the fourth quarter worth approximately $151,000. Finally, Takeda Pharmaceutical Co. Ltd. purchased a new position in shares of Rani Therapeutics in the fourth quarter worth $278,000. 30.19% of the stock is currently owned by hedge funds and other institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.